Gastrointestinal Bleeding in Percutaneous Coronary Intervention and Acute Coronary Syndromes

American Journal of Cardiology

Volumn 104, Issue 5 SUPPL., 2009, Pages 22C-29C

  Nikolsky, Eugenia ^a   Mehran, Roxana ^a   Stone, Gregg W ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; ESOMEPRAZOLE; FAMOTIDINE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PRASUGREL; WARFARIN;

ACUTE CORONARY SYNDROME; ANEMIA; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; CORONARY STENT; DRUG ELUTING STENT; ELDERLY CARE; ENTERIC COATED TABLET; ESOPHAGOGASTRODUODENOSCOPY; FLUID RESUSCITATION; GASTROINTESTINAL HEMORRHAGE; HIGH RISK POPULATION; HUMAN; KAPLAN MEIER METHOD; LOADING DRUG DOSE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT PLANNING;

EID: 68749086227     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.06.022     Document Type: Article

References (43)

1. Manoukian S.V., Feit F., Mehran R., Voeltz M.D., Ebrahimi R., Hamon M., Dangas G.D., Lincoff A.M., White H.D., Moses J.W., et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol 49 (2007) 1362-1368
2. Feit F., Voeltz M.D., Attubato M.J., Lincoff A.M., Chew D., Bittl J.A., Topol E.J., and Manoukian S.V. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention: an analysis of the REPLACE-2 trial. Am J Cardiol 100 (2007) 1364-1369
3. Chin M.W., Yong G., Bulsara M.K., Rankin J., and Forbes G.M. Predictive and protective factors associated with upper gastrointestinal bleeding after percutaneous coronary intervention: a case-control study. Am J Gastroenterol 102 (2007) 2411-2416
4. Nikolsky E., Mehran R., Lansky A.J., Caixeta A., Dangas G.D., Weisz G., Giuran I.B., Fahy M., Lincoff A.M., Witzenbichler B., and Stone G.W. Impact of gastrointestinal bleeding on outcomes of patients treated with contemporary antithrombotic strategies: pooled analysis from 3 randomized trials. J Am Coll Cardiol 53 suppl A (2009) A28 Abstract 2903-10
5. Chang C.M., Lau Y.K., Chu W.M., and Wong B.C. Gastrointestinal bleeding in patients receiving a combination of aspirin, clopidogrel, and enoxaparin in acute coronary syndrome. Am J Gastroenterol 103 (2008) 865-871
6. Yeomans N.D., Lanas A.I., Talley N.J., Thomson A.B., Daneshjoo R., Eriksson B., Appelman-Eszczuk S., Långström G., Naesdal J., Serrano P., et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 22 (2005) 795-801
7. Derry S., and Loke Y.K. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 321 (2000) 1183-1187
8. Kelly J.P., Kaufman D.W., Jurgelon J.M., Sheehan J., Koff R.S., and Shapiro S. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 348 (1996) 1413-1416
9. Lanas A., García-Rodríguez L.A., Arroyo M.T., Gomollón F., Feu F., González-Pérez A., Zapata E., Bástida G., Rodrigo L., Santolaria S., et al., Asociación Española de Gastroenterología. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 55 (2006) 1731-1738
10. Mehta S.R., Bassand J.P., Chrolavicius S., Diaz R., Fox K.A., Granger C.B., Jolly S., Rupprecht H.J., Widimsky P., Yusuf S., and CURRENT-OASIS 7 Steering Committee. Design and rationale of CURRENT-OASIS 7: a randomized, 2 × 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Am Heart J 156 (2008) 1080-1088
11. Hallas J., Dall M., Andries A., Andersen B.S., Aalykke C., Hansen J.M., Andersen M., and Lassen A.T. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 333 (2006) 726
12. Ng F.H., Wong S.Y., Chang C.M., Chen W.H., Kng C., Lanas A.I., and Wong B.C. High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease. Aliment Pharmacol Ther 18 (2003) 443-449
13. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., Rickenbacher P., Hunziker P., Mueller C., Jeger R., Bader F., Osswald S., Kaiser C., and BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting vs. bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
14. Hodgson J.M., Stone G.W., Lincoff A.M., Klein L., Walpole H., Bottner R., Weiner B.H., Leon M.B., Feldman T., Babb J., Dehmer G.J., and Society for Cardiovascular Angiography and Interventions. Late stent thrombosis: considerations and practical advice fore the use of drug-eluting stents: a report from the Society for Cardiovascular Angiography and Interventions Drug-eluting Stent Task Force. Catheter Cardiovasc Interv 69 (2007) 327-333
15. Aronow H.D., Steinhubl S.R., Brennan D.M., Berger P.B., Topol E.J., and CREDO Investigators. Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J 157 (2009) 369-374
16. Peters R.J., Mehta S.R., Fox K.A., Zhao F., Lewis B.S., Kopecky S.L., Diaz R., Commerford P.J., Valentin V., Yusuf S., and Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 108 (2003) 1682-1687
17. Wiviott S.D., Braunwald E., McCabe C.H., Montalescot G., Ruzyllo W., Gottlieb S., Neumann F.J., Ardissino D., De Servi S., Murphy S.A., et al., TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015
18. Hermosillo A.J., and Spinler S.A. Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous?. Ann Pharmacother 42 (2008) 790-805
19. Younossi Z.M., Strum W.B., Schatz R.A., Teirstein P.S., Cloutier D.A., and Spinks T.J. Effect of combined anticoagulation and low-dose aspirin treatment on upper gastrointestinal bleeding. Dig Dis Sci 42 (1997) 79-82
20. Mattichak S.J., Reed P.S., Gallagher M.J., Boura J.A., O'Neill W.W., and Kahn J.K. Evaluation of safety of warfarin in combination with antiplatelet therapy for patients treated with coronary stents for acute myocardial infarction. J Interv Cardiol 18 (2005) 163-166
21. Gurm H.S., Smith D.E., Collins J.S., Share D., Riba A., Carter A.J., LaLonde T., Kline-Rogers E., O'Donnell M., Changezi H., et al., Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: insights from a large regional registry of contemporary percutaneous coronary intervention. J Am Coll Cardiol 51 (2008) 529-535
22. Nikolsky E., Mehran R., Dangas G., Fahy M., Na Y., Pocock S.J., Lincoff A.M., and Stone G.W. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J 28 (2007) 1936-1945
23. Loeb D.S., Talley N.J., Ahlquist D.A., Carpenter H.A., and Zinsmeister A.R. Long-term nonsteroidal anti-inflammatory drug use and gastroduodenal injury: the role of Helicobacter pylori. Gastroenterology 102 (1992) 1899-1905
24. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. Helicobacter pylori in peptic ulcer disease. JAMA 272 (1994) 65-69
25. Manzano-Fernández S., Marin F., Martinez J.A., Cambronero F., Valdés M., Ruiz-Nodar J.M., Pérez-Berbel P., and Lip G.Y. Anaemia as predictor of gastrointestinal bleeding in atrial fibrillation patients undergoing percutaneous coronary artery stenting. QJM 101 (2008) 749-751
26. Cappell M.S., and Iacovone Jr. F.M. Safety and efficacy of esophagogastroduodenoscopy after myocardial infarction. Am J Med 106 (1999) 29-35
27. Siragusa S., Malato A., Lo Coco L., Cigna V., Saccullo G., Abbene I., Anastasio R., Caramazza D., Patti R., Arcara M., and Di Vita G. Gastrointestinal bleeding due to angiodysplasia in patients with type 1 von Willebrand disease: report on association and management. Haemophilia 14 (2008) 150-152
28. Cappell M.S. Safety and efficacy of colonoscopy after myocardial infarction: an analysis of 100 study patients and 100 control patients at two tertiary cardiac referral hospitals. Gastrointest Endosc 60 (2004) 901-909
29. Yavorski R.T., Wong R.K., Maydonovitch C., Battin L.S., Furnia A., and Amundson D.E. Analysis of 3,294 cases of upper gastrointestinal bleeding in military medical facilities. Am J Gastroenterol 90 (1995) 568-573
30. Abbas A.E., Brodie B., Dixon S., Marsalese D., Brewington S., O'Neill W.W., Grines L.L., and Grines C.L. Incidence and prognostic impact of gastrointestinal bleeding after percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol 96 (2005) 173-176
31. Spencer F.A., Moscucci M., Granger C.B., Gore J.M., Goldberg R.J., Steg P.G., Goodman S.G., Budaj A., FitzGerald G., Fox K.A., and GRACE Investigators. Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction?. Circulation 116 (2007) 2793-2801
32. Gilard M., Arnaud B., Cornily J.C., Le Gal G., Lacut K., Le Calvez G., Mansourati J., Mottier D., Abgrall J.F., and Boschat J. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 51 (2008) 256-260
33. Ho P.M., Maddox T.M., Wang L., Fihn S.D., Jesse R.L., Peterson E.D., and Rumsfeld J.S. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301 (2009) 937-944
34. Foley P., Foley S., Kinnaird T., and Anderson R.A. Clinical review: gastrointestinal bleeding after percutaneous coronary intervention: a deadly combination. QJM 101 (2008) 425-433
35. Rockall T.A., Logan R.F., Devlin H.B., and Northfield T.C. Selection of patients for early discharge or outpatient care after acute upper gastrointestinal haemorrhage: National Audit of Acute Upper Gastrointestinal Haemorrhage. Lancet 347 (1996) 1138-1140
36. Anderson J.L., Adams C.D., Antman E.M., Bridges C.R., Califf R.M., Casey Jr. D.E., Chavey II W.E., Fesmire F.M., Hochman J.S., Levin T.N., et al., American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction); American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association of Cardiovascular and Pulmonary Rehabilitation; Society for Academic Emergency Medicine. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 116 (2007) e148-e304
37. Chan F.K., Ching J.Y., Hung L.C., Wong V.W., Leung V.K., Kung N.N., Hui A.J., Wu J.C., Leung W.K., Lee V.W., et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 352 (2005) 238-244
38. Sung J., Lau J.Y., Ching J.Y., Leung W.K., Wu J.C., and Leung W.K. Early reintroduction of aspirin with proton pump inhibitor after endoscopic haemostasis for peptic ulcer bleeding: final results of a double blinded randomised study. Gut 56 suppl III (2007) A27
39. Ng F.H., Chan P., Kwanching C.P., Loo C.K., Cheung T.K., Wong S.Y., Kng C., Ng K.M., Lai S.T., and Wong B.C. Management and outcome of peptic ulcers or erosions in patients receiving a combination of aspirin plus clopidogrel. J Gastroenterol 43 (2008) 679-686
40. Lau J.Y., Leung W.K., Wu J.C., Chan F.K., Wong V.W., Chiu P.W., Lee V.W., Lee K.K., Cheung F.K., Siu P., Ng E.K., and Sung J.J. Omeprazole before endoscopy in patients with gastrointestinal bleeding. N Engl J Med 356 (2009) 1631-1640
41. Schaffalitzky de Muckadell O.B., Havelund T., Harling H., Boesby S., Snel P., Vreeburg E.M., Eriksson S., Fernström P., and Hasselgren G. Effect of omeprazole on the outcome of endoscopically treated bleeding peptic ulcers: randomized double-blind placebo-controlled multicentre study. Scand J Gastroenterol 32 (1997) 320-327
42. Sung J.J., Barkun A., Kuipers E.J., Mössner J., Jensen D.M., Stuart R., Lau J.Y., Ahlbom H., Kilhamn J., Lind T., et al., Peptic Ulcer Bleed Study Group. Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized trial. Ann Intern Med 150 (2009) 455-464
43. Walt R.P., Cottrell J., Mann S.G., Freemantle N.P., and Langman M.J. Continuous intravenous famotidine for haemorrhage from peptic ulcer. Lancet 340 (1992) 1058-1062